Immunoglobulin E antibody recognizing house dust mite allergen (IgE)

Immunoglobulin E (IgE) antibody recognizing house dust mite allergens refers to a subclass of antibodies produced by B cells upon sensitization to specific protein antigens from house dust mites (HDM), most notably groups such as Der p 1, Der p 2, and Der p 7. IgE antibodies bind with very high affinity to the FcεRI receptors on mast cells and basophils. When exposed to house dust mite allergens again, these IgE antibodies cross-link on cell surfaces, triggering immediate degranulation and release of inflammatory mediators (such as histamine and leukotrienes), resulting in type I hypersensitivity reactions that underlie clinical manifestations such as allergic rhinitis and asthma[1][2][3][4][6]. IgE levels and their specificity serve both as diagnostic and therapeutic targets in atopic diseases; therapeutically, anti-IgE monoclonal antibodies (e.g., omalizumab) are used to sequester free IgE, preventing receptor binding and downstream allergic inflammation. The significant specificity in the antigen-antibody interaction makes epitope mapping a key area for designing hypoallergens and improved immunotherapies[2][5].

Other names

IgEImmunoglobulin EAllergen-specific IgEAnti-house dust mite IgE

Neutralization of circulating IgE (Omalizumab, Ligelizumab); Inhibition of IgE binding to FcεRI on mast cells/basophils; Downregulation of IgE-mediated cell activation and degranulation.